1. |
Proposed treatment guidelines for paediatric HIV/AIDS |
|
Inpharma Weekly,
Volume &NA;,
Issue 1108,
1997,
Page 2-2
&NA;,
Preview
|
PDF (1239KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
2. |
Antibacterial challenges for the next millennium |
|
Inpharma Weekly,
Volume &NA;,
Issue 1108,
1997,
Page 3-4
Lee Baker,
Preview
|
PDF (2395KB)
|
|
摘要:
Approaching the next millennium, clinicians are faced with a double-edged dilemma with regard to antibacterial therapy: an increasing population of susceptible patients coupled with the spread of resistant bacterial pathogens. The role of the carbapenem antimicrobials, in particular meropenem, was discussed during an international symposium sponsored by Zeneca which was entitled ‘Carbapenems: taking &bgr;-lactams into the next millennium’. This symposium immediately preceded the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Toronto, Canada; September 1997].
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1108,
1997,
Page 5-5
&NA;,
Preview
|
PDF (1039KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
4. |
Nicotine policy required |
|
Inpharma Weekly,
Volume &NA;,
Issue 1108,
1997,
Page 6-6
&NA;,
Preview
|
PDF (1173KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
5. |
Examining antiretroviral resistance: Delta trial results |
|
Inpharma Weekly,
Volume &NA;,
Issue 1108,
1997,
Page 7-7
&NA;,
Preview
|
PDF (1089KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1108,
1997,
Page 8-8
&NA;,
Preview
|
PDF (1176KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
7. |
New generation multi-targeted antifolate active against solid tumours |
|
Inpharma Weekly,
Volume &NA;,
Issue 1108,
1997,
Page 9-10
Robert Carlson,
Preview
|
PDF (2227KB)
|
|
摘要:
LY-231514 [Eli Lilly; phase II] is a novel multi-targeted antifolate agent that inhibits a range of folate-requiring enzymes. Its clinical advantages are activity against a variety of solid tumours, a low toxicity profile and non-cross-resistance with platinum drugs. Results of 2 recent clinical trials with LY-231514 were presented at the European Cancer Conference (ECCO) '97 [Hamburg, Germany; September 1997]. A response rate of 33% was seen in a German trial combining LY-231514 with cisplatin in patients with a variety of solid tumours, and there was a response rate of 23% in a Canadian trial of LY-231514 monotherapy in patients with non-small-cell lung cancer (NSCLC). Myelosuppression was the dose-limiting toxicity in both studies. The German researchers concluded that the maximum tolerated dose of LY-231514 is 600 mg/m2when combined with cisplatin 100 mg/m2.
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1108,
1997,
Page 10-10
&NA;,
Preview
|
PDF (1121KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
9. |
Interferon-&bgr;-1a effective in relapsing-remitting MS |
|
Inpharma Weekly,
Volume &NA;,
Issue 1108,
1997,
Page 11-11
&NA;,
Preview
|
PDF (1066KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
10. |
News from the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)Toronto, Canada September 1997 |
|
Inpharma Weekly,
Volume &NA;,
Issue 1108,
1997,
Page 12-12
&NA;,
Preview
|
PDF (1216KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|